The rise of biologics has introduced manufacturing complexity that didn't exist a decade ago. Monoclonal antibodies, stem cell therapies, and mRNA platforms all demand specialist capability. This session explores how manufacturing is moving from a back-office function to a strategic differentiator.
- The biologics manufacturing challenge: what's required for mAbs, stem cells, and mRNA, and who can deliver it
- API sourcing and supply chain resilience: where ingredient-level decisions create downstream risk
- Manufacturing strategy for start-ups: why your CDMO relationship is a founding decision, not an operational one
- COGS and commercial viability: how unit economics at the manufacturing stage determine whether a product can reach market
- Manufacturing as a diligence factor: what acquirers and investors look for in your CMC package
Russell Miller
Josefina Correa
Cindy Cole
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.